Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes
Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. We undertake hit identification, hit-to-lead and lead optimisation projects and complete drug discovery programs across a range of therapeutic areas. In support of this, we have expanded our assay capability to include the state-of-the-art ImageXpress(R) Micro COnfocal (IXM-C) high-content imaging platform to provide multi-dimensional, high-throughput screening solutions to facilitate in-house drug profiling, bioscience and DMPK in vitro activities. Here we demonstrate the application of our integrated imaging platforms including the IXM-C and associated MetXppress(R) Image acquisition and analysis software to multiple phases of the drug discovery process.